Video released of rapid Alzheimer's improvement after new immune-based treatment

July 20, 2008

New research into the treatment of Alzheimer's disease reports improvement in language abilities using a novel immune-based approach. A video accompanying the research, published today in the open access journal BMC Neurology, documents rapid language improvement within minutes of using this new treatment.

Building on previous work by the same authors, published in BioMed Central's Journal of Neuroinflammation, this study focuses on the effect of the anti-tumor necrosis factor-alpha (TNF-alpha) drug, etanercept, on measures of verbal ability.

TNF-alpha, a critical component of the brain's immune system, normally finely regulates the transmission of neural impulses in the brain. The authors hypothesize that elevated levels of TNF-alpha in Alzheimer's disease interfere with this regulation. To reduce elevated TNF-alpha, the authors utilized a unique perispinal delivery method to administer etanercept.

The new BMC Neurology article provides preliminary evidence that the disrupted neural communication seen in Alzheimer's disease may be reversible.

According to the lead author of the study, Edward Tobinick, "There are limitations to the data presented; the clinical trial was open label, and not controlled. These caveats notwithstanding, the scientific rationale for the further investigation of anti-TNF-alpha treatment of Alzheimer's disease is compelling. In addition, family members, independent neurologists, and other independent observers have confirmed the clinical, cognitive, and behavioral improvement noted".

Disruption of language function, such as the ability to find words, is a common symptom in advancing Alzheimer's disease, and this BMC Neurology article is one of the first to suggest the possibility of a new therapeutic approach that may address these symptoms.
-end-
Alternative contact:

Charlotte Webber
+44 (0) 7825 317 342
charlotte.webber@biomedcentral.com

Notes to Editors:

1. The video is available at: http://w02.biomedcentral.com/download/pr/PPA1280.mov

2. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease
Edward L. Tobinick and Hyman Gross
BMC Neurology (in press)

During embargo, article available here: http://www.biomedcentral.com/imedia/1058950049198990_article.pdf?random=325992

After the embargo, article available at journal website: http://www.biomedcentral.com/bmcneurol/

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication

3. The lead author of the study, Edward Tobinick MD, is Director of the Institute for Neurological Research, a private medical group, inc., in Los Angeles. Dr. Tobinick has been investigating the role of TNF in neurological disorders for a decade. His research has provided new potential insight into the way immune molecules, such as TNF, may influence the function of the nervous system.

4. BMC Neurology is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of neurological disorders, as well as related molecular genetics, pathophysiology, and epidemiology. BMC Neurology (ISSN 1471-2377) is indexed/tracked/covered by PubMed, MEDLINE, CAS, Scopus, EMBASE, Thomson Scientific (ISI) and Google Scholar.

5. BioMed Central (http://www.biomedcentral.com/) is an independent online publishing house committed to providing immediate access without charge to the peer-reviewed biological and medical research it publishes. This commitment is based on the view that open access to research is essential to the rapid and efficient communication of science.

BioMed Central

Related Clinical Trial Articles from Brightsurf:

Clinical trial investigates gabapentin for alcohol use disorder
This randomized clinical trial investigated if gabapentin, a drug often used to treat nerve pain, would be useful in the treatment of patients with alcohol use disorder (problem drinking that becomes severe) and a history of alcohol withdrawal symptoms.

Electrical stimulation helps treat constipation in clinical trial
Electrical stimulation benefited women with constipation in a recent clinical trial published in Alimentary Pharmacology & Therapeutics.

Treatment of migraine pain in randomized clinical trial
Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.

First entirely digital clinical trial encourages physical activity
As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study.

HIV vaccine nears clinical trial following new findings
A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.

Sickle cell drug showing promise in clinical trial
An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.

Meditation goes digital in new clinical trial
Scientists at UC San Francisco have developed a personalized digital meditation training program that significantly improved attention and memory in healthy young adults -- a group already at the peak of brain health -- in just six weeks.

Could blockchain ensure integrity of clinical trial data?
UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain.

Eating crickets can be good for your gut, according to new clinical trial
A new clinical trial shows that consuming crickets can help support the growth of beneficial gut bacteria and that eating crickets is not only safe at high doses but may also reduce inflammation in the body.

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy®).

Read More: Clinical Trial News and Clinical Trial Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.